Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated

被引：0
|
作者：
Fang, W. F. [1 ]
Bu, Q. [2 ]
Wang, Q. M. [3 ]
Zhao, W. H. [4 ]
Wang, L. P. [5 ]
Dong, X. R. [6 ]
Chen, P. F. [7 ]
Wen, Z. B. [8 ]
Jia, J. [9 ]
Jiang, G. M. [9 ]
Zhang, L. [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Baotou Canc Hosp, Baotou, Peoples R China
[6] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[7] Zhuji Peoples Hosp, Zhuji, Peoples R China
[8] Peoples Hosp Gaozhou, Gaozhou, Peoples R China
[9] Dongguan Peoples Hosp, Dongguan, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
aumolertinib; high-dose; uncommon EGFR mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.09-07
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [31] EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
    Miura, S.
    Hsia, T-C.
    Hung, J-Y.
    Jung, H. A.
    Shih, J-Y.
    Park, C-K.
    Lee, S. H.
    Okamoto, T.
    Ahn, H. K.
    Lee, Y. C.
    Sato, Y.
    Lee, S. S.
    Mascaux, C.
    Daoud, H.
    Maerten, A.
    Popat, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S967 - S968
  • [32] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Lee, Yoo Jung
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [33] Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)
    Han, B.
    Fang, W.
    Chen, C.
    Zhang, W.
    Zhang, B.
    Yao, F.
    Shi, J.
    Yue, D.
    Qi, Y.
    Zhu, Z.
    Xie, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S287 - S287
  • [34] Investigation of age and smoking in NSCLC patients with uncommon EGFR mutations
    Maezawa, Yosuke
    Taguchi, Manato
    Kawakami, Takeshi
    Inui, Toshihide
    Okauchi, Shinichiro
    Numata, Takeshi
    Shiozawa, Toshihiro
    Miyazaki, Kunihiko
    Nakamura, Ryota
    Iguchi, Kesato
    Endo, Takeo
    Sakamoto, Tohru
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2024, 72 (02): : 107 - 113
  • [35] Rationale and Design of a Phase II Trial of Dacomitinib in Advanced NSCLC Patients with Uncommon EGFR Mutations
    Han, B.
    Zhang, B.
    Shi, C.
    Gao, Z.
    Zhong, H.
    Xiong, L.
    Gu, A.
    Wang, W.
    Chu, T.
    Zhang, W.
    Wang, H.
    Zhang, X.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [36] Clinicopathologic characteristics of NSCLC patients with uncommon EGFR mutations in Korea
    Kang, Hye Seon
    Kim, Kyu Yeon
    Lim, Jeong Uk
    Yeo, Chang Dong
    Kim, Ju Sang
    Kim, Seung Joon
    Lee, Sang Haak
    RESPIROLOGY, 2023, 28 : 100 - 100
  • [37] Impact of Clinicopathological Features on Efficacy of Osimertinib in Advanced NSCLC Patients With EGFR Mutations
    Wang, Y.
    Wang, Y.
    Tian, P.
    Han, R.
    Li, L.
    He, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S585 - S585
  • [38] Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients with NSCLC Harboring Sensitive EGFR Mutations
    Yamada, Y.
    Imai, H.
    Sugiyama, T.
    Minemura, H.
    Kaira, K.
    Kanazawa, K.
    Kasai, T.
    Kaburagi, T.
    Minato, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S908 - S908
  • [39] Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
    Lin, Ruiting
    Chen, Ruilian
    Chen, Zhiqiang
    Hu, Leihao
    Guo, Wei
    Zhang, Zexin
    Lin, Lizhu
    Chen, Hanrui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib
    Heon, S.
    Yeap, B. Y.
    Britt, G. J.
    Rabin, M. S.
    Jackman, D. M.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345